.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

SPRITAM Drug Profile

« Back to Dashboard
Spritam is a drug marketed by Aprecia Pharms Co and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.

This drug has twenty-four patent family members in eleven countries.

The generic ingredient in SPRITAM is levetiracetam. There are thirty-four drug master file entries for this compound. Ninety suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the levetiracetam profile page.

Summary for Tradename: SPRITAM

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: SPRITAM

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-004Jul 31, 2015RXYes9,339,489► subscribeY ► subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-002Jul 31, 2015RXNo9,463,160► subscribeY ► subscribe
Aprecia Pharms Co
SPRITAM
levetiracetam
TABLET, FOR SUSPENSION;ORAL207958-001Jul 31, 2015RXNo6,471,992► subscribeY ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: SPRITAM

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,114,072Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SPRITAM

Country Document Number Estimated Expiration
Japan2001512488► subscribe
Hong Kong1214787► subscribe
Canada2281473► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: SPRITAM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00028Netherlands► subscribePRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
00C/032Belgium► subscribePRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc